This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 12/04/2023 12:45

Fiscal Accounts

Schism in direct and indirect tax collections

India

Oct Fiscal Position

December 1, 2023

The government's fiscal accounts for October-23 show that 45% of the FY24BE fiscal deficit target was met, given healthy revenue and slowing expenditure growth. There is a split in tax collections, with healthy direct tax collections and weak indirect tax revenue. On the expenditure front, revenue expenditure growth stayed steady, while capex frontloading continued. We expect no material miss in FY24 capex vs BE, implying 2% average growth for the rest of the year over last year, after heavy frontloading in 7MFY24. Strong direct tax collections, robust PSU+RBI dividend, and better-than-expected nominal GDP growth will offset slippages in indirect taxes, divestment and food & fertilizer subsidy payments, implying that the 5.9% FY24BE GFD/GDP target is likely to be met.

Healthy direct tax collections driving overall growth amid anemic indirect taxes

The Centre's tax collections slowed down, albeit staying healthy in Oct-23, with gross tax collections rising 14% YoY to ~Rs18.3trn in Apr-Oct '23, faster than the budgeted growth of 10%. Direct tax collections have driven this increase, rising to Rs10.0trn (24% YoY vs 10% budgeted growth) as both, corporate taxes (Rs4.8trn; 17% YoY vs 11% budgeted) and income taxes (Rs5.2trn; 31% YoY vs 11% budgeted), maintained their healthy growth. Indirect tax collections continue to lag budgeted growth (Rs8.1trn, 3% YoY vs 10% budgeted), with GST (Rs5.3trn; 8% YoY, 12% budgeted), customs duty (Rs1.2trn; 1% YoY) and excise duty (Rs1.5trn; -9% YoY) collections all proving to be a drag on growth. Indirect taxes need to increase by ~19% during Nov-23 to Mar-24 over the same period last year, to meet FY24BE which looks unlikely given the moderating inflation and growth environment. Net tax revenue rose 16% YoY to Rs11.4trn.

Revenue expenditure growth stays steady...

Revenue expenditure (RevEx) growth stayed higher than budgeted. Total RevEx rose to ~Rs18.5trn in Apr-Oct '23 (7% YoY vs 1% budgeted), with interest payments rising 13% YoY to ~Rs4.8trn (vs 17% budgeted), while major subsidy payments stayed lower than last year (Rs2.3trn; -3% YoY vs -28% budgeted). The high run-rate, so far, implies that revenue expenditure can actually decline ~4% during Nov-23 to Mar-24 over the same period last year and still meet the FY24BE target.

...and capex frontloading continues

Capex for 7MFY24 was Rs5.5trn (34% YoY vs 37% budgeted) as the Centre continues to frontload capex ahead of the upcoming Parliamentary elections, despite slowing a tad since Sep-23. Capex has been led by Railways (Rs1.6trn; 53% YoY vs 51% budgeted), while spending on Roads & highways (Rs1.7trn; 17% YoY vs 25% budgeted) and Defence (Rs747bn; 8% YoY vs 8% budgeted) has seen only a modest rise. Transfers to states have dropped off since Sep-23, but remain higher than budgeted (Rs655bn; 93% YoY vs 71% budgeted). Capex frontloading in 7MFY24 means that only a modest increase of 2% during Nov-23 to Mar-24 over the same period last year will be enough to meet the FY24BE of Rs10.0trn, and we do not expect any slippage on this front.

Fiscal deficit under control, and seems to be on track

The fiscal position remains under control due to healthy revenue and slower expenditure growth. The Centre's fiscal deficit for Apr-Oct '23 was Rs8.0trn, coming 6% higher than last year (vs 2% budgeted), and meeting 45% of the FY24BE fiscal deficit target vs 44% in the same period last year. The revenue deficit of Rs2.8trn is 27% lower than last year's, indicating that the higher overall deficit so far is mainly due to capex frontloading, with lower revenue expenditure. Higher direct tax collections, RBI/PSU dividends and better-than-expected nominal GDP growth will offset slippages from indirect taxes, divestment and food & fertilizer subsidy payments, implying that the 5.9% FY24BE GFD/GDP target will be met.

Madhavi Arora

madhavi.arora@emkayglobal.com +91 22 6612 1341

Harshal Patel


harshal.patel@emkayglobal.com +91 22 6624 2434

Key highlights:

- FYTD gross tax revenue up 14% YoY
- RevEx up 8%, capex higher by 34%
- 45% of the budgeted FD target achieved; 5.9%
 FY24BE GFD/GDP target to be met



Exhibit 1: 7MFY24 fiscal deficit is tracking last year's trend, and is much lower than the pre-Covid average



Source: CGA, Emkay Research

Exhibit 2: Monthly receipts of the Indian central government (Rs bn)

				Chg. (%	5)	FYTD (A	Apr-Oct)	Chg. (%)	FY24 BE	FY24	FY23
	Oct-23	Oct-22	Sep-23	yoy	mom	2024	2023	yoy	/FY23 RE	% of BE	% of P
Gross tax revenues	2,152	2,178	4,301	(1)	(50)	18,345	16,096	14	10	55	53
Direct taxes	1,003	883	3,036	14	(67)	10,032	8,082	24	10	55	49
Corporate tax	307	353	2,123	(13)	(86)	4,820	4,106	17	11	52	50
Income tax	696	531	912	31	(24)	5,212	3,976	31	11	58	49
Indirect taxes	1,113	1,262	1,226	(12)	(9)	8,071	7,804	3	10	53	56
Customs duty	182	367	227	(50)	(20)	1,244	1,229	1	11	53	58
Excise duty	255	258	250	(1)	2	1,502	1,657	(9)	6	44	52
GST	676	637	750	6	(10)	5,325	4,919	8	12	56	58
CGST	716	728	619	(2)	16	4,686	4,136	13	12	58	58
IGST	(159)	(194)	17	(18)	(1,042)	(171)	61	(380)			
Com cess	119	103	114	16	5	810	722	12	12	56	57
Other taxes	37	32	38	15	(2)	201	159	27	4	239	47
Net tax revenues	1,416	1,591	3,564	(11)	(60)	11,431	9,865	16	7	51	57
Non-tax revenues	290	212	272	37	7	2,548	1,668	53	15	84	58
Non-debt capital receipts	28	15	48	88	(41)	223	322	(31)	1	27	45

Source: CGA, Emkay Research

Exhibit 3: Direct taxes are in line to overshoot FY24BE targets, while indirect taxes need a significant pick up over last year

	FY24 Budgeted growth (%)	Apr-Oct growth (%)	Monthly run- rate (Apr-Oct, INR bn)	Reqd monthly run- rate (Nov- Mar, INR bn)	over last
Gross tax revenues	10	14	2,621	3,053	6
Direct taxes	10	24	1,433	1,657	0
Corporate tax	11	17	689	881	6
Income tax	11	31	745	759	(8)
Indirect taxes	10	3	1,153	1,443	19
Customs duty	11	1	178	217	20
Excise duty	6	(9)	215	378	23
GST	12	8	761	848	17

Source: CGA, Emkay Research


This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 12/04/2023 12:45 PM

Emkay Research is also available on www.emkayglobal.com and CGA EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 4: Monthly fiscal aggregates of the Indian central government (Rs bn)


				Chg. (%	6)	FYTD (Ap	r-Oct)	FYTD Chg. (%)	FY24 BE /		FY24	FY23P
	Oct-23	Oct-22	Sep-23	(yoy)	(mom)	2024	2023	yoy	FY23 RE	FY24BE	% of BE	% of P
Total receipts	1,734	1,818	3,883	(5)	(55)	15,907	13,856	15	10	27,163	59	56
Total expenditure	2,753	3,201	4,474	(14)	(38)	23,944	21,437	12	8	45,031	53	51
Revenue expenditure	2,190	2,540	3,306	(14)	(34)	18,475	17,347	7	1	35,021	53	50
Interest payments	608	445	1,168	37	(48)	5,451	4,812	13	15	10,800	50	52
Major subsidies	253	400	257	(37)	(1)	2,317	2,389	(3)	(28)	3,747	62	45
Food	157	189	122	(17)	29	1,109	1,351	(18)	(31)	1,974	56	50
Fertilizer	96	210	130	(54)	(27)	1,197	1,027	17	(22)	1,751	68	41
Oil	-	2	4	(100)	(100)	11	11	1	(75)	23	50	16
Agriculture and farmers' welfare	6	8	13	(28)	(53)	62	75	(17)	5	1,250	5	65
Education	74	3	111	2,038	(33)	387	195	99	13	1,129	34	33
Health and family welfare	1	2	3	(37)	(51)	0	0	41	11	839	0	33
Rural development	1	0	0	77	236	7	6	16	(12)	1,600	0	60
Capital expenditure	563	661	1,168	(15)	(52)	5,469	4,090	34	37	10,010	55	56
Defence	73	51	195	44	(62)	747	692	8	8	1,714	44	46
Railways	141	138	299	2	(53)	1,567	1,023	53	51	2,400	65	64
Roads and highways	152	243	462	(37)	(67)	1,716	1,461	17	25	2,586	66	71
Housing and urban affairs	2	14	52	(83)	(95)	123	105	17	10	260	47	44
Transfers to states	55	282	188	(80)	(71)	655	340	93	71	1,300	50	37
Others	139	(66)	(28)	(311)	(600)	661	468	41	66	1,750	38	45
Fiscal deficit	1,018	1,383	590	(26)	73	8,037	7,581	6	2	17,868	45	44
Revenue deficit	484	737	(530)	(34)	191	2,798	3,848	(27)	(22)	8,699	32	36
Primary deficit	411	938	(578)	(56)	171	2,586	2,770	(7)	(13)	7,068	37	34

Source: CGA, Emkay Research



Source: CGA, Emkay Research


Exhibit 6: Expenditure needs to increase marginally in remaining FY24, to meet the BE target




Source: CGA, Emkay Research

This report is intended for team emkay @ whitemarguesolutions com use and downloaded at 12/04/2023 12:45 PM Emkay Research is also available on www.emkayglobal.com and CGA EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 7: Direct-tax overshoot to be offset by higher RevEx and lower indirect tax





Source: Emkay Research estimates

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 12/04/2023 12:45 PM Emkay Research is also available on www.emkayglobal.com and CGA EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

his report is intended for team emkay @ whitemarouesolutions com use and downloaded at 12/04/2023 12:45 PM Emkay Research is also available on www.emkayglobal.com and CGA EMKAY<GOS-Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors at defined in the Securities and Futures Act, Chapter 289 of Singapore.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGESL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1. the securities recommended in this report as of May 12, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- З EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of May 12, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the May 12, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- 7 EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

bis report is intended for team. emkay @ whitemarquesolutions.com use and downloaded at 12/04/2023 12:45 PM Emkay Research is also available on www.emkayglobal.com and CGA EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.